Esketamine monotherapy demonstrated beneficial antidepressant effects at multiple doses for patients with treatment-resistant depression, according to results of a phase 4 randomized trial published ...

I have a friend who goes to a ketamine clinic for fun. He doesn’t have depression or PTSD, but heard that ketamine was a ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, ... Esketamine, the S-enantiomer of ketamine, was approved by the FDA in 2019 for the treatment of TRD.

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Home; Articles; The dopaminergic effects of esketamine are mediated by a dual mechanism involving glutamate and opioid receptors ...

Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression, a randomized, double-blind trial found. Among 379 participants in the efficacy ...

Esketamine combined with an SNRI is more effective for treatment-resistant depression (TRD) than when paired with an SSRI. Analysis of over 55,000 patients showed that the SNRI combination ...

During the 4-week treatment period, adults ages 22 to 64 (mean age 42-43, 86% women, 78% white) without psychotic features of DSM-5-confirmed MDD participated in three CT-152 or sham sessions per ...

The FDA first approved esketamine nasal spray for treatment-resistant depression in combination with an oral antidepressant, as reported by Medscape Medical News.. The expanded indication as ...

My mission is to deliver compassionate, personalized, and innovative care, empowering you to reclaim your mental health, improve your overall well-being and elevate your quality of life.